Apotex Well being Corp., one among Canada’s largest pharmaceutical corporations, is getting ready to go public on the Toronto Inventory Change with an providing that might increase as much as C$1.2 billion. The corporate filed a preliminary prospectus on Might 28, 2026, underneath the ticker APTX.
What the providing seems like
The IPO is structured as a mixture of newly issued treasury shares and secondary shares. The secondary element comes primarily from SK Capital Companions, the controlling shareholder trying to monetize a part of its stake.
Estimates for the providing measurement vary between C$750 million and C$1 billion, with a possible higher ceiling of C$1.2 billion relying on demand.
Apotex’s financials give the itemizing some severe backing. The corporate reported C$3.5 billion in income alongside C$374 million in earnings.
Apotex has constructed its enterprise across the generics pharmaceutical market, working throughout the Americas and India with a considerable workforce.
Strategic context and up to date strikes
In April 2026, the corporate struck a partnership with Cumberland Prescribed drugs aimed toward increasing its specialty drug portfolio within the US market.
SK Capital Companions, the personal fairness agency that controls Apotex, is utilizing the IPO partly as a liquidity occasion. The inclusion of secondary shares within the providing means a number of the proceeds go on to present shareholders moderately than into firm coffers.
What this implies for traders
The valuation math begins with these C$3.5 billion in income and C$374 million in earnings. Comparable generics corporations are inclined to commerce at modest earnings multiples relative to the broader pharma sector.
The Cumberland Prescribed drugs partnership provides a wrinkle price monitoring. If Apotex can efficiently construct out its US specialty drug presence, that adjustments the expansion narrative meaningfully, as specialty pharma instructions increased margins and stickier income streams.
